SNUBI Research :: SysBiol  (835 talks)
All  Seminar  BioEMR  xMutant  SysBiol  MAInfo  J.Club  TopicSem  BookReading    This week    New Talks   Old SysBiol page    Help

ADD NEW USER

Go to team wiki page
Goal
  • Deciphering personal genomes

  • Date
  • Weekly meeting : every Monday, 11:00

  • Members
  • ξ, , ȼȯ, , Ӽ, ̽

  • :   ǥ:    /Ű:    ¥:   

    2024-02:
    19 전예진 the use of two sample methods for MR on single large datasets 
    26 임성수 Identification SAM pairs from TCGA dataset 

    2024-01:
    15 이시은 G-CDM : genomic information to current OMOP-CDM 
    22 조민아 Comparison between matching and sex exact matching 

    2023-12:
    23 전예진 DGIdb ; new Query Score and updated Interaction Score 

    2023-11:
    13 임성수 Identifying synthetic anti-metastasis pairs from TCGA dataset - external validation 
    27 조민아 Workflow of extracing eid considering self-report 

    2023-10:
    16 조민아 AACR-KCA poster: Gene signatures for prediction of survival in bladder cancer patients treated with immune checkpoint inhibitor 

    2023-09:
    18 임성수 Identifying SAM pairs from TCGA dataset 

    2023-08:
    07 임성수 Identifying SAM pairs - calculate GVB by defining LOF mutations 
    21 조민아 Code for network analysis of pair-wide gvb  

    2023-07:
    03 임성수 Identifying SAM pair from TCGA-SKCM 
    10 조민아 Code of trend of GVB in m-core analysis 

    2023-06:
    05 조민아 igraph: r package for network graph (code)  
    05 조민아 igraph: r package for network graph (code)  
    05 조민아 igraph: r package for network graph (code)  

    2023-05:
    15 임성수 (Replication) Identifying SAM pairs from TCGA-COAD patients 

    2023-04:
    02 임성수 (Replication) Overall process of identifying SAM gene pairs from TCGA 
    17 조민아 Downloading data using pyega3 

    2023-03:
    27 전예진 pgx-passport 

    2023-02:
    13 조민아 RNA-seq deconvolution 

    2023-01:
    05 안세환 test    

    2022-12:
    26 전예진 FoldX_variant stability and effect prediction 

    2022-11:
    21 조민아 SCISSOR: tutorial 

    2022-10:
    03 ... õ 
    10 ... ü 
    17 조민아 All variants of CEMIP2 genes in ulcerative colitis patients 
    24 부은경

    2022-09:
    26 전예진 type of pharmacogenomic evidence and limitation 

    2022-08:
    01 조민아 Application of long-read sequencing to elucidate complex pharmacogenomic regions: a proof of principle 

    2022-07:
    18 안세환 Adjusted Rand Index between haplogroups and populations  

    2022-06:
    20 안세환 Evaluate the haplogrouping method by DNA evolution pairwise distances 
    27 조민아 Euclidean distance-optimized data transformation for cluster analysis in biomedical data (EDOtrans) 

    2022-05:
    16 안세환 Summary of variants in 25 pharmacogenes 
    23 조민아 JASPAR database: an open-access database of curated, non-redundant transcription factor (TF) binding profiles 

    2022-04:
    05 부은경 Exploration of genotype-phenotype interactions and prevalence of genetic variants 
    25 조민아 The complete sequence of a human genome (github) 

    2022-03:
    29 조민아 Comparing coverage of genotyping of previous study 

    2022-02:
    22 조민아 Extracting disease age of onset in UKBB 

    2022-01:
    11 조민아 Genozip: a universal extensible genomic data compressor 
    18 부은경 Case study of thiopurine intolerance in IBD  

    2021-12:
    07 조민아 The UKBB clinical data of results in UC patients group 
    14 부은경 Study ideas for analyzing recurrent event data and correcting potential bias 
    28 안세환 TPMT star-alleles in high-coverage T1GP 

    2021-11:
    02 부은경 Analysis of rare and ultra-rare variants in gene based tests 
    23 안세환 Comparison of phasing strategies for whole human genomes 

    2021-10:
    05 조원일 genetic correlation 
    12 안세환 Segmented haplotype estimation and imputation tools (SHAPEIT4) 
    12 안세환 Segmented haplotype estimation and imputation tools (SHAPEIT4) 
    19 윤미선 A Benchmark Dataset for Automatic Segmentation and Labeling of Individual Ribs on Chest X-rays 
    26 조민아 Liftover using r package, rtracklayer 

    2021-09:
    28 부은경 Comparison of TIL incidence rate in combined IBD dataset 

    2021-08:
    03 조민아 The CCGWAS R package : a tool for case-case association testing of two different disorders based on their respective case-control GWAS results 
    10 부은경 Survival Analysis Using Frailty Models 
    17 조원일 genetic correlations of polygenic disease traits 
    24 안세환 TPMT star-alleles and haplogroups of Health Showcase data 

    2021-07:
    06 안세환 Querying against cell viability data(PRISM) in CMap LINCS website 
    20 윤미선 Group-based pharmacogenetic prediction 
    27 ֿ Comparing distribution of variants in PD genes among 1KGP3 populations 

    2021-06:
    01 윤미선 Stargazer genotyping 
    08 ֿ Revised association between PGx haplotype frequency and drug use in the UKBB population 
    15 조민아 Review: Benchmarking the Human Leukocyte Antigen Typing Performance of Three Assays and Seven Next-Generation Sequencing-Based Algorithms 
    29 조원일 Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data 

    2021-05:
    04 조동영 Pharmacogenomics Application and Challenges 
    04 조동영 Pharmacogenomics Application and Challenges 
    11 유경훈 Opportunities and challenges for the computational interpretation of rare variation in clinically important genes 

    2021-04:
    08 조민아 Review: Transfer learning enables prediction of CYP2D6 haplotype function 
    13 부은경 A systematic comparison of pharmacogene star allele calling bioinformatics algorithms: a focus on CYP2D6 genotyping 
    20 조원일 Review: Pharmacogenimics_lancet 
    20 조원일 Review: Pharmacogenimics_lancet 
    20 조원일 Review: pharmacogenomics_lancet 
    27 안세환 Calling star-alleles from NGS data 

    2021-02:
    18 홍진희 ukbb genotype 
    18 홍진희 ukbb genotype 
    18 홍진희 ukbb genotype 

    2021-01:
    07 유경훈 Global distribution of CYP2C19 risk phenotypes affecting safety and effectiveness of medications 
    14 홍진희 manual of using GP dataset in ukbb 

    2020-12:
    03 ֿ Refining the clinical definition of clopidogrel adverse events 
    17 조민아 PHASE: A program for reconstructing haplotypes from population data 

    2020-11:
    05 조민아 Introduction of Taiwan biobank database 
    05 조민아 Introduction of Taiwan biobank database 
    12 부은경 FastTargetPred: a program enabling the fast prediction of putative protein targets for input chemical databases 
    14 조민아 Review: Neutrophil-to-lymphocyte ratio in inflammatory bowel disease - as a new predictor of disease severity 
    17 조민아 All variants of CEMIP2 genes in ulcerative colitis patients 
    17 조민아 All variants of CEMIP2 genes in ulcerative colitis patients 
    17 조민아 Downloading data using pyega3 
    17 조민아 Downloading data using pyega3 
    17 조민아 Downloading data using pyega3 in python 

    2020-10:
    22 ֿ Primary care prescription drug use and related actionable drug-gene interactions in the Danish population 

    2020-08:
    31 ֿ Identifying populations likely to benefit from pharmacogenomic testing 

    2020-07:
    06 Genotype Data in UKBiobank 
    13 ֿ The implementation of pharmacogenomics for older adults 
    23 홍진희 synthetic association study 
    23 홍진희 synthetic association study 
    23 홍진희 synthetic association study 
    23 홍진희 synthetic association study 
    23 홍진희 synthetic association study 
    23 홍진희 synthetic association study 
    23 홍진희 synthetic association study 
    23 홍진희 synthetic association study 
    23 홍진희 synthetic association study 
    23 홍진희 synthetic association study 
    27 조민아 Gene set enrichment analysis tools 

    2020-06:
    01 부은경 Additional analysis to identify candidate variants associated with PD 
    08 안세환 Mechanism of action lists in L1000 data 
    15 한봄 Assessment of case-control studies 

    2020-05:
    04 COVID-19 data in the UK Biobank 
    11 ֿ Contribution of genetic variation in drug-drug-gene-interactions 
    11 ֿ Contribution of genetic variation in drug–drug–gene interactions 
    18 홍진희 illumina sequencing WES 111 samples 
    25 조민아 Association analysis-Plink and Snpsift 

    2020-04:
    06 안세환 The Comparative Toxicogenomics Database 
    13 한봄 The utility of surrogate markers in predicting HLA alleles associated with adverse drug reactions in Vietnamese 
    20 최선 Database for screening the toxicity of peptides 
    27 ȿ [review] Development of a Genomic Data Flow Framework: Results of a Survey Administered to NIH-NHGRI IGNITE and eMERGE Consortia Participants 

    2020-03:
    02 Comparing polygenic risk scores between male and female depressive patients 
    09 ֿ The design and implementation strategy of European pharmacogenomics through the U-PGx consortium 
    09 ֿ The design and implementation strategy of European pharmacogenomics through the U-PGx consortium 
    19 홍진희 Whole exome seuqence varinat calling in 2 ALL patient    
    19 홍진희 Whole exome seuqence varinat calling in 2 ALL patient 
    19 홍진희 Whole exome seuqence varinat calling in 2 ALL patient 
    23 조민아 Preprocessing WES data of EOAD (Early Onset Alzheimers Disease) 
    23 조민아 Preprocessing WES data of EOAD (Early Onset Alzheimers Disease) 
    23 조민아 Preprocessing WES data of EOAD (Early Onset Alzheimers Disease) 
    30 부은경 Variants associated with PD 

    2020-02:
    24 ȿ [Review] Personalized Medicine and the Power of Electronic Health Records 
    24 ȿ [Review] Personalized Medicine and the Power of Electronic Health Records 

    2020-01:
    06 부은경 Synergyfinder: Calculate and Visualize Synergy Scores for Drug Combinations 
    13 안세환 Visualize interpretable pattern from LINCS-L1000 
    20 한봄 HLA*IMP 

    2019-12:
    02 ȿ [Review] The Role of Modeling in Clinical Information System Development Life Cycle 
    09 The GenomeAsia 100K Project enables genetic discoveries across Asia 
    16 Identifying genes related to age of onset in Major Depressive Disorder (MDD) patients 
    23 ֿ Examination of Parkinsons disease cSAG deleteriousness using GVB score and pathway analysis 

    2019-11:
    11 안세환 Introduction to Genetic Algorithm 
    25 유경훈 Towards precision medicine: interrogating the human genome to identify drug pathways associated with potentially functional, population-differentiated polymorphisms 

    2019-10:
    14 Distribution of in silico prediction scores for NUDT15 variants identified in gnomAD database 
    21 Analysis of OPLL 
    28 ֿ Evaluation of candidate SAGs using tacrolimus sample WXS data 

    2019-09:
    02 OPLL analysis  
    09 ֿ Candidate SAG evaluation using tacrolimus sample data 
    16 안세환 Subtype of Cell Lines in L1000 data 
    23 한봄 Biomarkers of adverse drug reactions 
    23 한봄 Biomarkers of adverse drug reactions 
    30 유경훈 Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation 

    2019-08:
    12 Whole-genome sequencing of rare disease patients in a national healthcare system - Genomics England 100,000 genomes project 
    12 유경훈 Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research    
    26 ȿ [review] Genomic information for clinicians in the EHR: lessons learns from clinGen and eMerge 

    2019-07:
    01 Association of CRIM1 variant and 6-mercaptopurine-induced adverse effects in childhood acute lymphoblastic leukemia 
    01 유경훈 Hubble2D6: A deep learning approach for predicting drug metabolic activity 
    08 Analysis of age at onset in depression 
    15 ֿ ADR related synthetic association study: data processing flow and statistics 
    22 안세환 The GCTx format and cmap{Py, R, M, J} packages: resources for optimized storage and integrated traversal of annotated dense matrices 

    2019-06:
    03 안세환 Errors in importing Leukemia Data 
    10 한봄 Read quality check using CaReal 
    24 ȿ [Review] Standardizing terms for clinical pharmacogenetic test results: consensus terms from the CPIC 

    2019-05:
    13 Evaluating potential drug targets through human loss-of- function genetic variation 
    20 Parallel processing in R  
    27 ֿ Candidate SAG interpretation based on inter-ethnic variability 

    2019-04:
    08 ֿ A disease-drug database to support drug prescribing based on patient pharmacogenomics test results 
    15 안세환 Select available columns in cBioPortal mutation file 
    22 한봄 Definitions of HLA typing terms 
    22 한봄 Definitions of HLA typing terms 
    30 유경훈 Clinical use of current polygenic risk scores may exacerbate health disparities 

    2019-03:
    07 안세환 File Formats for cBioPortal 
    18 ȿ Assessment of serologic markers on liver fibrosis: descriptive statistics 
    25 An open resource of structural variation for medical and population genetics 
    25 유경훈 DGIdb 3.0: a redesign and expansion of the drug-gene interaction database 

    2019-02:
    07 Consensus Path DB 
    14 ֿ Evaluation of synthetic association detection using gene deleteriousness scores in hearing loss case 
    28 한봄 Marker selection for genetic case-control association studies 

    2019-01:
    03 한봄 Data quality control in genetic association studies 
    10 유경훈 Drug Targetor: a web interface to investigate the human druggome for over 500 phenotypes 
    17 Combination chemotherapy in advanced gastric cancer 
    24 ȿ Assessment of Diagnostic Usefulness of Liver Fibrosis Predictive Markers  
    31 Difference of genetic architectures in men and women with depression 

    2018-12:
    06 Analysis of Early response in depression 
    13 ֿ ITPA gene variants protecting against anemia as a case of synthetic association 
    20 안세환 Protein domain layer in VVA Plot 

    2018-11:
    08 유경훈 Analysis of population-specific pharmacogenomic variants using next-generation sequencing data 
    15 ConnectivityMAP database in CLUE portal 
    22 ȿ Query design strategy for detecting NSAIDs induced ADRs  
    29 Descriptive data analysis: in vitro functionality of 337 PGx variants 

    2018-10:
    04 Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions 
    11 Geneset Deleterious Burden Analysis (GS-DBA) 
    18 ֿ Characteristics of candidate SAGs with regard to ethnicity 
    25 안세환 The Cochran-Armitage Trend Test(CATT) in result table of VVA 

    2018-09:
    06 한봄 Study of Glucocorticoid-Induced Diabetes Mellitus 
    13 TP53 Paclitaxel SC Network is Prognostic Factor on Urogenital Cancers 
    20 유경훈 Integrating rare genetic variants into pharmacogenetic drug response predictions 
    27 ȿ GDM DB migration to NGS server 
    27 ȿ GDM DB migration to NGS server 

    2018-08:
    02 Worldwide Distribution of Cytochrome P450 Alleles 
    09 ֿ Using TCGA for validation of synthetic association  
    16 Age of onset in MDD 
    23 안세환 Add knowledge bases to VVA plot 

    2018-07:
    05 유경훈 Interpretation of genes related to early response by antidepressant group 
    12 NGS biomarker for busulfan ADR 
    12 NGS biomarker for busulfan ADR 
    19 한봄 Steroid Induced Hyperglycemia 
    26 ȿ [review] A standard database for drug repositioning 

    2018-06:
    07 Current progress and future prospects in organoid research 
    21 ֿ Signatures and examples of synthetic association 
    21 ֿ Signatures and examples of synthetic association 
    28 안세환 Apply VVA to GDM 

    2018-05:
    03 한봄 Tumor-only analysis on rare cancer samples 
    10 안세환 Knowledge Bases for VVA 
    17 유경훈 Review: Ki Database 
    24 A Next Generation Connectivity-Map L1000 for drug treatment profiles 
    31 ȿ TCGA Clinical Data Structure Review  

    2018-04:
    05 Functionalization of Variants in Clinically Actionable Pharmacogenes (F-CAP) 
    12 ȿ Exploratory analysis: KAERS dataset  
    19 Analysis of onset age in depression 
    19 Analysis of onset age in depression_meet 
    26 ֿ Evaluation of extracting genes with variants in synthetic association to ADR biomarkers 

    2018-03:
    08 안세환 VVA review and future work 
    08 안세환 VVA review and future work 
    08 안세환 VVA review and future work 
    15 한봄 Tumor-only analysis on rare cancer samples 
    22 유경훈 Sub-group of SIOH patient groups according to drug response record. 
    29 RS-ADR data portal development, Firebase & vue.js 

    2018-02:
    08 The comparative analysis of the gene regulatory network according to the pathological stages reveals the characteristics of metastasis in gastric cancer 
    14 PharmVar database overview 
    14 PharmVar database overview 
    14 PharmVar database overview 
    28 ֿ Interpretation of genes in synthetic association to PGx variants: a case study 

    2018-01:
    11 ֿ Pathway annotation of genes synthetically associated to GWAS PGx variants 
    18 Synthetic Dosage Cytotoxicity for prioritization of chemotherapy 
    31 ֿ Pathway enrichment analysis for FDA and GWAS PGx variants 

    2017-12:
    07 Non-linear model to predict cytotoxic drug response 
    14 ֿ Gene set annotation for genes synthetically associated with PGx variants 
    28 ȣ 1265 Potential drug targets gene 

    2017-11:
    02 ȣ SSRIs drugs with Pharmacogenomic snp and adr 
    09 K-CDM: Conversion of EMR data to OMOP format 
    16 ֿ Using standard queries to analyze ADR risks across multiple institutions 
    16 ֿ Using standard queries to analyze ADR risks across multiple institutions 
    23 PharmCAT review 
    30 ȣ druggable proteome classification and examples 

    2017-10:
    09 Korean Clinical Imaging Guidelines and clinical decision support system 
    16 ֿ Variant level analysis of genes in synthetic association to PGx variants: case for rs4646244 TA, AA 
    16 ֿ Variant level analysis of genes in synthetic association to PGx variants: case for rs4646244 TA, AA 
    26 Extracting information from PharmGKB 

    2017-09:
    11 ֿ Extracting variants associated to drug response from the NHGRI GWAS Catalog 
    18 DMET data processing protocol 
    25 ȣ SNRIs Antidepressants and Pharmacogenomic information 
    25 ȣ SNRIs Antidepressants and Pharmacogenomic information 

    2017-08:
    07 ֿ Results of predominant and synthetically associated genes to PGx alleles 
    07 ֿ synthetic association study 
    07 ֿ synthetic association study 
    07 ֿ synthetic association study 
    07 ֿ synthetic association study 
    28 ȣ Most-Prescribed Antidepressants - Mental Health Daily report 

    2017-07:
    03 ֿ Updated statistics for determining ADR risk according to PGx variant status using synthetic association 
    10 Chemotherapy and adverse drug reactions in Acute Myeloid Leukemia  
    17 SCAN and PACdb : pharmacogenomics databases 
    17 SCAN and PACdb : pharmacogenomics databases 
    24 ȣ Tricyclic antidepressants and similarity of interacting genes 
    31 Finding genes targeted by GDSC drugs 

    2017-06:
    05 Repositories where researchers can download or upload genomic data 
    12 Roles of Solute Carriers and the functional consequences of polymorphism 
    19 ȣ Tricyclic antidepressants physiologic action and ADR 
    26 A tool for discovering drug sensitivity and gene expression associations in cancer cells 

    2017-05:
    01 Roles of ATP-Binding Cassette transporters and the functional consequences of polymorphism 
    15 ȣ P-glycoprotein polymorphism and drug adverse response 
    29 ֿ ADR risk according to 8 PGx variant statuses using synthetic association 

    2017-04:
    03 ePGA: AWeb-Based Information System for Translational Pharmacogenomics 
    10 ȣ Pharmacogenetics of Membrane Transporters ABCB1 
    17 Gastric cancer metastasis network analysis 
    24 ֿ Statistics of updated PGx variants for synthetic association analysis 

    2017-03:
    06 Weakly supervised learning 
    13 ֿ Visualization of variants grouped by genes in synthetic association with PGx variants 
    20 ̰ȭ Review Cases of Genomic Data Warehouse  
    27 Effects of variants in transporter genes on drug efficacy and toxicity  

    2017-02:
    06 ȫֿ Transporter-madiated drug-drug interactions 
    23 Effects of variants in transporter genes on drug efficacy and toxicity 
    27 ȣ Detecting Antibiotic Resistance Genes 

    2017-01:
    02 The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half Life 
    02 The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half Life 
    09 ȣ PharmGKB Clinical annotation search 
    16 Inference cancer drug prognosis via cell line model 
    23 ֿ Chromosomal distribution of variants synthetically associated with pharmacogenomic SNPs 

    2016-12:
    05 Integrative analysis for identifying the best anticancer therapy based on genomic features 
    12 ֿ Determining adverse drug event risk according to FDA SNP genotype 
    12 ֿ Determining adverse drug event risk according to FDA SNP genotype 
    12 ֿ Determining adverse drug event risk according to FDA SNP genotype 
    12 ֿ Determining adverse drug event risk according to FDA SNP genotype using synthetic association 
    19 ȫֿ [DDGI DB] TRANSFORMER 
    26 SFINX database 

    2016-11:
    07 ȫֿ Human BioPathway Databases 
    07 ȫֿ Results of predominant and synthetically associated genes to PGx alleles 
    14 DMET data processing protocol 
    21 Review of BRENDA database 
    27 ȣ drug side effects information – ex Metformin 

    2016-10:
    03 SFINX database 
    10 validation result of PharmSafe by variant score filter 
    17 ȣ Bina - develops next-generation genomic management  
    19 ȣ Mutual exclusive network and inference target from drug sensitivity 
    19 ȣ Mutual exclusive network and inference target from drug sensitivity 
    19 ȣ Mutual exclusive network and inference target from drug sensitivity  
    31 ֿ Results of variant-centric approach for MRONJ 
    31 ֿ Human BioPathway Databases 

    2016-09:
    12 ̰ȭ Gender Difference in ADR - Review of Article (Systematic Analysis of Adverse Event Reports for Sex Differences in Adverse Drug Events, 2015, Scientific Report)  
    19 ֿ Risk for ADEs in South Korean geriatrics from Beers Criteria medications 
    26 ȫֿ Physiologically Based Pharmacokinetic Modeling 
    9 WGCNA Network analysis of Microarray data 

    2016-08:
    01 ֿ Distribution of F10 mutations in the 1000 Genomes phase 3 population 
    08 ȫֿ Knowledge based Pharmsafe Database 
    15 unknown  
    15 Exome Sequencing Project 
    29 ȣ Cloud Platform - Pricing 

    2016-07:
    04 MetaCyc database review 
    11 ȣ TB database 
    18 Pharmacoinformatics tools in Drug discovery and Development activities. 
    25 Microarray analysis (Illumina), research results 

    2016-06:
    06 Intratumor heterogeneity influences the interaction of neoplastic cells with ECM proteins 
    13 ֿ Detecting candidate variants of MRONJ occurrence 
    20 ȫֿ The UCSF-FDA TransPortal 
    27 Therapeutic Targets Database review 

    2016-05:
    02 ȫֿ Pharmsafe Application 
    09 [Review] DSigDB 
    16 20 Most frequently prescribed therapeutic classes : National Ambulatory Medical Care Survey - CDC 
    23 ȣ genotype and HIV drug 
    30 PGRN/PGX tool and Drug Metabolizing Enzymes (DMEs) among Different Population 

    2016-04:
    04 ȣ HER2-positive breast anticancer drug and genotype 
    11 Ethical, social and legal issues in pharmacogenomics    
    18 Identification of Drug relative genes predictive of Cancer survival in Chemotheraphy agent 
    25 ֿ CNV and gene expression profile in 1000 Genomes phase 3 population 
    25 ֿ CNV and gene expression profile in 1000 Genomes phase 3 population 
    25 ֿ Association between CNV and gene expression using 1000 Genomes data 
    25 ֿ Copy number variation and gene expression in 1000 Genomes phase 3 population 
    25 ֿ Association between CNV and gene expression using 1000 Genomes data 

    2016-03:
    01 DGIdb Database review and research examples 
    08 ֿ Review of very important pharmacogenes in PharmGKB 
    14 ȫֿ pharmsafe report review 
    21 DrugBank XML structures and parsing 
    21 DrugBank XML structures and parsing 
    28 Database Review : SuperTarget 

    2016-02:
    02 ̰ȭ BRONJ gene centric analysis 
    09 Integration of DrugBank and KEGG 
    16 ȣ cmap data and perturbation sensitivity 
    23 CYP450 and Personalized Medicine using 1000 genomes  

    2016-01:
    05 PharmPortal Updated Database Schema 
    12 Discussion about validation of PK weighted drug score 
    19 ֿ Model on predicting patients likely to benefit from preemptive genotying 
    26 PharmSafe Report calculations 

    2015-12:
    15 ֿ Review of clinical outcomes from pharmacogenotyping 
    22 Fine-tuning plans 
    29 ֿ Indications and pharmacologic action of frequently prescribed drugs in US and South Korea 

    2015-11:
    03 ֿ Review of pharmacoeconomic analysis methods 
    24 ֿ Application of breakeven analysis for preemptive genotyping 

    2015-10:
    13 ֿ Review of pharmacogene-related ADRs in Koreans 

    2015-09:
    01 ֿ Distribution of drug usage extent in HIRA 2011 patients 
    22 ֿ Overview of Korea Adverse Event Reporting System 

    2015-08:
    04 Core functions of PharmPortal 
    11 ֿ Trend in predicted number of people with serious AE over year 2011 
    18 Statistics of input drug-gene pair with Km and Kcat 

    2015-07:
    07 ֿ Refined figures for patient demographics and calculation results of preemptive PG study 
    11 ֿ Refined figures for patient demographics and calculation results of preemptive PG study 
    28 ֿ Progress of figures on number of patients predicted to have AEs based on genotype 

    2015-06:
    16 ֿ Additional results of preemptive genotyping calculation algorithm using 1KP ancestry 
    16 ֿ Additional results of preemptive genotyping calculation algorithm using 1KP ancestry 

    2015-05:
    06 ֿ Calculation workflow for showing need for preemptive genotyping  
    26 ֿ Calculation scheme for predicting number of people with adverse events using ancestry-weights 

    2015-02:
    17 ֿ Statistics of processed year 2011 HIRA data 

    2015-01:
    06 ֿ Comparison of statistics for inpatient and outpatient prescriptions of year 2011 
    27 ֿ Overview of HIRA 2011 statistics 

    2014-12:
    16 ֿ Statistics of year 2011 HIRA data and PREDICT study data 
    16 ֿ Statistics of year 2011 HIRA data and PREDICT study data 

    2014-11:
    11 DMET data processing protocol 
    11 DMET data processing protocol 
    11 DMET data processing protocol 
    11 DMET data processing protocol 
    25 ֿ Calculating number of preventable adverse events with HIRA data using PREDICT algorithm 

    2014-10:
    22 ֿ Statistics of year 2011 HIRA patient and drug data 

    2014-09:
    11 Busulfan case reports of identifited ADR associated gene with personal genome sequence 
    18 Drug Transporters in Drug Efficacy and Toxicity Review 
    18 Drug Transporters in Drug Efficacy and Toxicity Review 
    18 Drug Transporters in Drug Efficacy and Toxicity Review 
    24 ֿ Calculation of number of potential adverse events prevented from preemptive genotyping-meta analysis process 
    24 ֿ Calculation of number of potential adverse events prevented from preemptive genotyping-meta analysis process 

    2014-08:
    05 Discussion about case study result of ADR related gene detection 
    12 Therapeutic Targets Database review 
    19 ֿ Examination of number of preventable adverse events using PREDICT algorithm and HIRA drug claims data 
    26 ֿ Review of Iodine website 
    31 ֿ Review of the roles and mechanisms of proteins encoded by pharmacogenes 

    2014-07:
    01 ֿ Examination of number of patients prescribed drugs with clinically severe AEs modulated by variant alleles 
    08 Discussion about weight score of drug-gene pair without Km value 
    15 systemetic validation result of ADR gene detection 
    15 systemetic validation result of ADR gene detection 
    15 CNV and gene expression profile in 1000 Genomes phase 3 population 
    22 ֿ Examination of the frequency of pharmacogenetic medication prescribing in Korea 
    22 ֿ Examination of the frequency of pharmacogenetic medication prescribing in Korea 
    29 Discussion about results of weighted drug score (log transformation) 

    2014-06:
    03 Discussion of validation result of ADR causal gene detection 
    10 ֿ Review of FDA-approved drugs with pharmacogenomic information in their labeling 
    17 Discussion about validation set of Km weighted drug score 
    24 Discussion of validation result of ADR causal gene detection 

    2014-05:
    07 Compare the result calculating weighted drug score using Km mean value and Km median value 
    13 Review and cleansing of DITOP database 
    20 ֿ Examination of data in Korea Health Insurance Review & Assessment Service 
    27 Discussion for weight score of Km value 

    2014-04:
    01 Discuss the result of pharmacodynamic sub-module construction related to ADR 
    08 ֿ Review of Cancer Genome Project database 
    08 ֿ Review of Cancer Genome Project database  
    08 ֿ Review of Cancer Genome Project database  
    08 ֿ Review of Cancer Genome Project database  
    15 DrugBank 4.0 Update Review 

    2014-03:
    04 Workflow of weighted drug score with kinetic parameter 
    11 Find module related to ADR class in 1000Genome individual 
    18 ֿ Role and mechanisms of drug targets, enzymes, transporters, and carriers 
    18 ֿ Role and mechanisms of drug targets, enzymes, transporters, and carriers 
    25 Review : HumanCyc database  

    2014-02:
    04 Apply CCLE data to personal pharmacogenomics research 
    11 How SNP heterozygosity affects gene expressions 
    18 Research to find out ADR mechanism 

    2014-01:
    14 Quality check for exome sequence(COPD vs TCGA) 
    20 The Cancer Cell Line Encyclopedia (CCLE) - review and discussion about its personal pharmacogenomic application 
    28 Pharmacokinetics - review of kinetic parameters 

    2013-12:
    03 ̼S review of Pharmacogenomics(Pharmacogenomics in Action) 
    17 κ Target CpG site enrichment method for methylation sequencing 
    24 Experimental methods for RNA sequencing 
    31 Summary of exome sequencing processing pipeline 

    2013-11:
    05 The MedSeq Project : Integration of Whole Genome Sequencing into Clinical Medicine 

    2013-10:
    05 κ Genome sequencing for healthy individuals 
    15 Finding the lost factors in exome sequencing data 
    29 Recent research trend of genetic variant scores 

    2013-09:
    03 Review and statistics of PharmGKB 
    10 current statistics for transcriptome reference : ensembl 
    23 ̼S current statistics for GWAS catalog 
    24 ̼S current statistics for GWAS catalog 

    2013-08:
    06 Analysis of epigenetic modification by bisulfite conversion 
    20 Review of SIFT algorithm 

    2013-07:
    09 Potential etiologic and functional implications of genome-wide association loci for human disease and trait 
    09 Potential etiologic and functional implications of genome-wide association loci for human disease and trait 
    16 κ Genetic rearrangement induced by LCR block 
    27 CpG island analysis for personal genome interpretation 

    2013-06:
    04 Personal genome related DB review(4) - GWASdb 
    15 Personal genome related DB review(5) - Genevar 
    25 ̼S DB review(7) - Interpretome 

    2013-05:
    11 Personal genome related DB review(1) - SNPedia 
    14 ̼S Phenopedia and Genopedia 
    21 κ Personal genome related DB review(3) - SNP Nexus  
    21 κ Personal genome related DB review(3) - SNP Nexus  

    2013-04:
    06 COPD mRNA editing analysis scheme 
    13 ̼S dbGAP paper review 
    16 κ Methylation Analysis of 10 Lymphoma(MALT type) 
    27 case report of Target sequencing and its validation in 22 family 
    30 Review of eQTL analysis 

    2013-03:
    19 ̼S plan for team 
    26 Discussion application SNAP score on genome interpretation 

    2013-01:
    09 Development of gene-environment interaction database for personal genome interpretation 
    16 Called SNVs Comparison Between Two Platform Sequencing Techonologies and Promethease. 
    23 ̼S Risk prediction method & x-men 
    31 MedCassandra - apply for new snubi sequence 

    2012-12:
    12 ̰ȭ AML-paired exome seqeuncing data analysis  
    26 Integration for Chip-Seq and RNA-seq data 

    2012-11:
    07 Blood genotyping for pretransfusion testing 
    14 Aplication of pharmacogenomic knowledge to clinic 
    21 Cancer Genomeancer (review for ICGC data portal) 

    2012-10:
    26 Middle of report Genomancer 

    2012-09:
    08 Hypertension meta analysis  
    14 Plan for Server-client communication. 
    14 Environmental Facter Viewer in Genomancer 
    18 Updated plan for genomancer included server-client communication codes 
    26 Review for Encode(1) : An integrated encyclopedia of DNA elements in the human genome 
    26 Risk assessment for alcoholism 

    2012-08:
    01 Review of PharmGKB data open policy 
    03 Overview of Genomancer test version 
    03 Development of gene-environment interaction database for personal genome interpretation 
    22 Meta analysis tool 
    29 Result of Meta Analysis 
    31 ̼S Meta analysis 1st result and plan for RP & x-man 
    31 Overview of Genomancer test version and Demo 

    2012-07:
    04 Web Interface for Meta Analysis 
    04 ̰ȭ Metaanalysis Plan for Obese X-men 
    05 Web Interface for Meta Analysis 
    11 ̼S Meta analysis plan  
    18 Genomancer UI frame 
    20 Genomancer discussion 
    25 Reads align with Bowtie2 

    2012-06:
    08 Genomancer App version  
    08 ̼S Clinical prediction and X-men 
    08 Development of gene-environment interaction database for personal genome interpretation 
    13 Result of Pilot study for Genomancer Xman Sleep 
    20 Overview of Genomancer modified design 
    29 Development of gene-environment interaction database for personal genome interpretation 

    2012-05:
    03 ̼S Clinical prediction and X-men 
    04 Plan for Genomancer 
    04 Gene - Disease - Environment for personal genome interpretation 
    09 Development of gene-environment interaction database for personal genome interpretation 
    17 RNA-Seq Analysis pipeline and fastq quality control 
    18 Development of gene-environment interaction database for personal genome interpretation  
    23 Discussion meta-analysis process for risk assessment 

    2012-04:
    04 Summary of pharmacogenomics 
    18 Genomancer draft design 

    2012-03:
    14 Summary of pharmacogenomic research 
    21 naive results of 1000 genome analysis 
    27 Summary and Overview of Personal Genome Deciphers team 
    27 ȹ  
    30 Development of gene-environment interaction database for personal genome interpretation 

    2012-02:
    01 Phenotypic signature practicality. 
    01 PGSeminar presentation overview 
    01 Development of gene-environment interaction database for personal genome interpretation 
    08 Development of gene-environment interaction database for personal genome interpretation 
    08 â TCGA 2008 nature journal 
    15 Development of gene-environment interaction database for personal genome interpretation 

    2012-01:
    02 Weekly progress 
    02 Environment and Disease Risks 
    11 Semantic Map for Phenotypic Signature 
    11 The development of priority weighting approach for disease-environment interaction based on personal genome 
    11 â COSMIC database parsing 
    18 SNUBI Sequence Preprocessing Final Report 
    18 Algorithms to prioritize candidate genes underlying diseases 
    18 Introduction of MeSH and studies related to Gene-Environment 
    25 Personal Genome Seminar Preview: Establishing phenotypic signatures to infer relevant phenotypic characteristics using semantic similarity calculation. 
    25 Interpreting personal genome variations using gene-disease-environment interaction network analysis 
    25 The Development of Priority Weighting Approach for Disease-Environment Interaction Based on Personal Genome 

    2011-12:
    13 Gene-set wise approach using KEGG databases 
    13 Visualization of gene-disease-environment interaction network analysis 
    13 â Normal(1000Genome) to Cancer(CGP) 
    13 Genetic risk platform 
    21 Platform for estimation and visulization of personal disease risk prediction 
    21 Plan for Pharmacogenomic phenotype 
    21 â Variant parsing of 1000 Genome data 
    28 Finding Drug-Drug interaction using pharmacogenomic phenotype 
    28 Research in progress 
    28 Future study for improvement 
    28 â 1000 Genome data parsing 
    28 Structured Phenotype 

    2011-11:
    02 Construct a Network with Variants Information on Disease Network 
    02 VAAST result 
    02 How to report for sequence analysis result 
    02 Genetic risk reporting 
    08 Gene-set Wise Approach for Disease Susceptibility Genes on PubMed.    
    08 Geographic differences in allele frequencies of susceptibility SNPs for cardiovascular disease 
    16 Poster overview 
    16 Gene-set wise approach using KEGG pathway.    
    16 HGDP(Human Genome Diversity Project) 
    16 Problems of gene-disease-environment interaction network analysis 
    22 â Best Practice Variant Detection with the GATK v3 
    22 Phenotypic signature using genomic variant annotation on semantic network.  
    22 Drug response phenotype standardization and SNP-phenotype reliability score 
    22 HuGE Navigator Localization 
    30 Genotype Look and Feel: Genome Data Mining for Phenotypic Signature. 
    30 Human Variome Project 

    2011-10:
    05 SNUBI Sequence Variants Analysis Pipeline and Visualization Tool 
    05 Work process 
    05 Implementing risk prediction service 
    06 Seminar review 
    12 PG Seminar preview 
    12 Pharmacogenomics annotation seminar review 
    12 Implementing risk prediction service 
    19 Unknown Variant Effect Imputation by Nearby Annotated Variants. 
    19 The Phenotype Standardization Project 
    26 Unmapped variants analysis overview 

    2011-09:
    02 PharmGKB annotation 
    02 Gene-environment interaction 
    02 Visualization of variant annotation results 
    02 Genetic Risk Prediction 
    06 Genetic Risk Prediction 
    14 Genetic score(post-test prob) 
    14 Future work 
    21 Mapping rsID, genotype for each disease 
    21 Gene-environment interaction using 2011 data 
    28 Future process and review in pharmacogenomics 
    28 Implementing risk prediction service 
    28 patients statistics 

    2011-08:
    05 Atul Paper Replication 
    05 Factors extraction for etiome replications 
    05 SOAP2, SOAP 
    17 GDS, GPL Parsing 

    2011-07:
    01 Alignment tools and LASTZ 
    04 Pharmacogenetics analysis process 
    04 Relationship between Disease and Etiological factors for deciphering Human genome 
    04 Assessment of overrepresented variant-set in rare disease associated genetic variants 
    22 SNUBI Sequences SIFT Analysis 
    29 Quick Look: Tabix    
    29 Personal genome variants annotation 
    29 introduction & installation of Galaxy LIMS 

    2011-06:
    03 File Formats for Genome 
    03 Genetic Counseling & Service 
    10 SNP Set Enrichment Analysis Associations with Rare Variants 
    10 Building SNP-Phenotype association database    
    10 MEDLINE/PubMed Baseline Repository (MBR) 
    17 Time Table 
    17 Replication Plan    
    21 SSEA Data Set from Publication    
    21 LASTZ introduction, PharmGKB mapping strategy. 
    23 LANCET Replication Progress - Time schedule 

    2011-05:
    06 Pharmaceutical Response in Personal Sequence 
    13 Stepping toward Personalized Medicine in Personal Sequence 
    13 Indentity evaluation 
    13 23andMe Review 
    21 Rare Disease Knowledgebase and Exome Sequence Data 
    27 about etiome 
    27 Disease-associated SNP Database 
    27 systemetic validation result of ADR gene detection 

    2011-04:
    08 discuss about integration of analysis result and biological knowledgebase 
    08 2011-04-08 Team NBA Meeting Report 
    15 Relication Design & Progess 
    15 Individual topic paper outline 
    19 simple idea for graduation paper 
    26 Present situation of Personal Genome Research 

    2011-03:
    25 paper review about COSMIC, Oncomine 

    2010-12:
    29 a 

    2010-11:
    03 SVG in HTML5    
    04 Paper Review for SNP data analysis 
    24 Concept of AXP 
    25 SVG 

    2010-10:
    20 ppt 
    27 GWAS 
    31 temp_seminar 

    2010-08:
    15 Path Search 
    26 gene2mesh 

    2010-07:
    01 summary 
    02 GSEA, GWAS 
    08 i-GWAS4GSEA 
    22 PANTHER version 6 

    2010-06:
    03 AXPIII 
    03 individual project research 
    10 Organization of AXP concept 
    10 Replication of perturbation sensitivity 
    10 Paper review process 
    17 Additional thinking on perturbation sensitivity 
    17 Human Disease-Drug Network 
    24 progress of perturbation network analysis 
    3 m-core, distribution of degree 

    2010-05:
    07 data entries 
    27 Syntactic Integration - PID 
    27 Extract Reactome Data 

    2010-04:
    01 Datamodel of Reactome, PID and INOH 
    01 Pathway Structure comparison(KGML, BioPAX, Reactome, PID) 
    01 metagraph 
    08 PathwayStuio Review 
    08 Pathway Structure comparison(KGML, BioPAX, Reactome, PID, SBML) 
    08 Comparison of Ontologies 
    15 Extracting Entry Data of Apoptosis from KGML, Reactome 
    15 Requriement Analysis of Pathway Systems_revision 
    15 Comparison of Melecule Role Ontologies 
    17 Requriement Analysis of Pathway Systems_revision II 
    19 HPD: an online integrated human pathway database enabling systems biology studies 
    22 How to consist of entries extracted from pathway DBs. 
    22 the Event Ontology & How to extract info using Kegg API 
    28 ArrayXPathIII Database Schema 
    29 The ArrayXPathIII Database Schema Ver1.0 
    29 OMIM gene pathway interaction 

    2010-03:
    01 Meta Path Review 
    01 KEGG API 
    04 Modeling Comparison ver2 
    04 KGML 
    11 Pathway Models Review 
    11 reactome 
    11 Thetharus Vs KEGG classification 
    12 Pathway Models Review 
    18 Pathway Structure Comparison 
    18 Reactome model and comparison with NCI PID 
    21 Pathway Structure comparison(KGML, BioPAX, Reactome) 
    25 Pathway Structure comparison(KGML, BioPAX, Reactome) 
    25 INTERACTION PATHWAY DATABASE 
    25 Visualizing biological pathways 

    2010-02:
    04 Enrichment study with data 
    04 Killer application 
    04 The systems biology graphical notation review(progress) complement 
    11 GSEA & MEA 
    11 PathComp 
    11 KGML(KEGG Markup Language)_ver2 
    18 pahtcomp 
    18 Analysis & KGML 
    18 The Regulation of Gene Expression 
    25 Network Analysis 
    25 KGML vs BioPAX 

    2010-01:
    15 Enrichment Analysis 
    15 Visualization Tools inquiry and improvement(ver.3) 
    15 Network analysis 
    21 advanced Enrichment Analysis 
    21 ArrayXPath3 Interface & Visualization 
    28 statistics 
    28 ArrayXPath3 Interface Renewal 

    2006-07:
    06 ArrayXPath: map on homologene    
    06 α Another ANOVA viwer in BioCANDI [biocandi]
    13 ¼ Issues on PathTalk 

    2006-06:
    01 similarity among normal tissues and cancer by biological context 
    01 Interim report of clustering columns in GEO data table : Platform [Technology typeGEOdata column]
    08 ѹ̷ Meta analysis using AB chip & cDNA chip 
    08 CellMAP progrerss 
    15 HDF 츮 Ѱ? 
    15 α A Primer on Kernel Methods [kernel]
    22 ¼ Issues on PathTalk [pathtalkkernel]   
    22 Lattice similarity work progress [biolattice]
    29 Remaking extended schemata & result of mapping to primary schema [in situ oligomappping resultGEO]

    2006-05:
    04 ¼ [PathTalk] Geodesic distance in pathway graph [PathTalk]
    04 Similarity measure between lattices : toxicant data [BioLattice]
    11 α Correlation dependent on third gene expression level 
    11 ѹ̷ Multimarker predictive model using machine learning algorithm 
    18 CellMap for pathway [pathway mapintegration of GO and pathway]
    18 Approach of Clustering columns in GEO data table : Platform [technology typedata columnplatformsampleGEO]
    25 ๰ü DB 䱸  
    25 ¼ PathTalks - reasearch plan [PathTalks]

    2006-04:
    06 Pathway mapping 
    13 α Temporal relation between GO 
    20 ѹ̷ Multimarker predictive model using machine learning algorithm 
    20 ¼ BioLattice: similarity of lattices [BioLattice]
    27 Depth-First Search Object Search & Drawing Object Network 
    27 Difficulty in importing GEO data into Xperanto 

    2006-03:
    03 ¼ Visualization and evaluation of structural relationship between gene clusters and biological pathways [PathTalk]
    03 GEO, for better approach 
    09 DB Update Interface Ȳ 
    09 PathMeSH + miRNA progress 
    16 BioLattice application II 
    16 α Functional enrichment of sequential pattern with MIPS functional category 
    23 ѹ̷ Integrating Classification and Association Rule Mining 
    30 ¼ Geodesic distance in pathway graph 
    30 Present state of GEO Localization 

    2006-02:
    03 ¼ PathTalk: Visualization and evaluation of structural relationship between gene clusters and biological pathways [PathTalk]
    10 ѹ̷ Applying rule mining and FCA to protein with profile & pattern 
    10 Rule mining from concept lattice 
    24 ѹ̷ Association Mining and Formal Concept Analysis 

    2006-01:
    06 α Application of Genetic Algorithm to sequential pattern mining on gene expression data 
    06 ѹ̷ Comparative analysis of array CGH algorithms 
    13 ¼ PathTalk: diameters of gene sets on topological structure of pathways [PathTalk]
    13 ArrayXPathIII: Implementation of Mutual Information 
    20 Rule mining from Concept Lattice 
    20 α Sequential pattern mining Ȯ flow chart 

    2005-12:
    02 Genome Annotation Report 
    02 ѹ̷ AB chip мȹ 
    16 Evaluation of matrix factorization methods for the analysis of DNA microarray gene expression data 
    16 α Rationale for sequential pattern mining 
    23 ¼ PathTalk: Visualization and evaluation of structural relationship between gene clusters and biological pathways [PathTalk]
    23 ArrayXPathIII: localize KEGG pathways using KEGG API 
    30 Orientia genome annotation update 

    2005-11:
    04 α spm ִ  
    11 ѹ̷ Plan for protein-ontology lattice 
    18 matrix factorization for clustering and pattern discovery  
    25 ¼ DispLay: different sequential patterned moduLes in array data [DiffCoexpression]
    25 Plan for ArrayXPath and add a function 

    2005-10:
    07 research plan 
    07 ๰ü DB  
    14 ѹ̷ What is the next step? 
    21 (progress) Matrix factorization for clustering and molecular pattern discovery on Microarray 
    21 ¼ Kullback-Leibler divergence to measure the biological relevance of given cluster 
    28 Idea for ArrayXPath III 
    28 correlation of transcriptome and interactome 

    2005-09:
    02 ¼ ̻  
    09 Frame work of GRIP 
    09 Short BioLattice Manuscript 
    16 GRIP Pathway Mapping 
    16 α Cluster viewer upgrade 
    23 Matrix factorization fo microarray data analysis 
    23 ѹ̷ aCGH_GLAD 
    30 Idea of pathway merge 

    2005-08:
    05 α Get the facts about SGD GO-slim 
    05 ѹ̷ Molecule Role Ontology 
    12 ¼ Required analysis modules in Xperanto 
    12 BioLattice manuscript (artworks) 
    19 newGRIP manuscript 
    19 α The very first step in mouse lymphoma microarray analysis 
    26 Issues for application MF to microarray data analysis 

    2005-07:
    01 α Temporal relation between GO terms 
    08 ѹ̷ Further steps for protein classification 
    08 ¼ Filters in Xperanto-BioCANDI 
    15 Review of Matrix factorization (ICA ) 
    15 Heterogeneous Ensemble 
    22 Chip2Chip 
    29 Biological mode and knowledge based conversion for microarray 
    29 PhactaX SOAP ӻ ڷᱳȯ 

    2005-06:
    03 Cluster Ensemble and Its Applications in Gene Expression Analysis 
    03 ¼ Learning Model for pathway extension 
    10 Summary GRIP concept for manuscript 
    10 Biological interpretation of BioLattice results 
    17 attributes of New GRIP 
    17 Microarray Analysis Component ڷǥ XML Schema  

    2005-05:
    06 Item sets for newGRIP 
    06 Representation and visualization of cluster relationship 
    13 Gene & Gene Family Ȳ 
    13 Microarray Analysis Component ڷǥ ȯ 
    20 ѹ̷ Protein classification from protein domain composition and GO using formal concept analysis 
    27 review of issues for ICA 

    2005-04:
    01 ¼ RunDEDS 
    01 PathCross: the first step 
    08 BioLattice analysis results 
    08 Current Localized Sequence object status 
    15 Development plan for the component-based Microarray analysis environment 
    15 α Summary of sequential pattern mining 
    22 ѹ̷ Analysis & interpretation of tripartite lattice 
    22 Web-DEDS  
    29 Combining Multiple Clusterings 
    29 ¼ Plan to complete PathPlus [pathplus]

    2005-03:
    03 Manuscript for AXP 2.0 
    03 BioLattice work report 
    10 GRIP Specs. (..) 
    10 Microarray High-Level Data Analysis Modeling (Use Case Modeling) 
    17 α FESD: a Functional Element SNPs Database in human 
    17 ѹ̷ Database localization & How to make matrix? 
    24 Progress in DEDS 
    24 Approaches to Discover Emerging Patterns in bio-data 

    2005-02:
    03 Supporting evidence to modular organization 
    03 α Current agenda and Overlap matrix visualization 
    17 ѹ̷ Three-way interpenetration among protein domain, protein, and GO using FCA 
    24 Algorithm of ICA - FastICA 
    24 Application of emerging patterns for multi-source data classification and analysis 

    2005-01:
    06 MDS errors... 
    06 α Manuscripting sequential patterning mining in gene expression data 
    13 The development present status of ArrayXPath 2.0 
    13 Algorithm of ICA 
    20 ѹ̷ GOTree Machine (GOTM) 
    20 GRIP object 
    27 ѹ̷ Review GO tool 
    27 MAGE-OM Highlevel Data Analysis Ű Ȯ 
    27 Strategy for ArrayXPath 

    2004-12:
    02 ArrayXPath plan for NGIC project 
    02 GO-FCA work progress 
    09 ӻڷý MGED 𵨸 ڷ 
    09 ѹ̷ VitaPad: Visualization Tools for the Analysis of Pathway Data 
    16 α Sequential pattern mining ⺻ ũе 
    16 GRIP Object property  
    23 Estimating gene networks Using Bayesian network 
    23 Items of ArrayXPath 2.0 
    30 Progress note for BioLattice 
    30 ӻڷý MGED ڷ Է¼ 

    2004-11:
    04 ArrayXPath: version 2.0 
    04 GO-based cluster annotation using Formal Concept Analysis 
    11 α Relevant work review of k-gOPSM 
    11 ӻڷ ڷ  
    18 ¼ CGH-Explorer  
    18 GRIP Version 2 Intro
    ( GRIP Ver.2 modelling open/closed integration issue 鿡 )
     
    25 ѹ̷ Searching pathway databases 
    25 Using BN for estimating gene networks from microarrays and biological knowledge 

    2004-10:
    07 α Order-based subspace clustering 
    07 ӻڷ ̿ڷ  
    14 ¼ Determining differentially expressed genes in a microarray expression dataset 
    14 GEO Platform Description header Sample Description header м 
    21 ѹ̷ Possibility of systematic Multiple-pathways 
    21 Bayesian Network & example of application 

    2004-09:
    23 PathMesh - Writing manuscript - 
    23 Total context view of clusters using FCA 

    powered by SNUBI